[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518745":3},{"organization":4,"outcomesModule":7,"designInfo":43,"detailedDescription":49,"studyPopulation":42,"armGroups":50,"interventions":57,"overallOfficials":62,"centralContacts":66,"locations":71,"responsibleParty":85,"collaborators":42,"id":88,"slug":42,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":42,"eligibilityCriteria":92,"healthyVolunteers":89,"sex":93,"minAge":42,"maxAge":94,"enrollmentInfo":95,"targetDuration":42,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":42,"overallStatus":73,"whyStopped":42,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Hong Kong Children's Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":42},[9],{"measure":10,"description":11,"timeFrame":12},"Graft failure-free, GVHD-free survival","From the date of treatment start until the date of graft failure or GVHD or death from any cause, whichever comes first, assessed up to 1 year","up to 1 year",[14,17,20,23,26,29,32,35,39],{"measure":15,"description":16,"timeFrame":12},"Overall survival","From the date of treatment start until the date of death from any cause, assessed up to 1 year",{"measure":18,"description":19,"timeFrame":12},"Proportion of patients who develop relapse among those with malignant diseases","Relapse is defined as reappearance of biopsy-proven malignant disease after complete remission",{"measure":21,"description":22,"timeFrame":12},"Proportion of patients who develop graft failure","Graft failure is defined as donor cells \\\u003C5% in whole blood",{"measure":24,"description":25,"timeFrame":12},"Proportion of patients who develop infection","Any microbiologically documented infections are included",{"measure":27,"description":28,"timeFrame":12},"Proportion of patients who develop acute graft-versus-host disease","Acute graft-versus-host disease is defined by MAGIC criteria",{"measure":30,"description":31,"timeFrame":12},"Proportion of patients who develop chronic graft-versus-host disease","Chronic graft-versus-host disease is defined by NIH criteria",{"measure":33,"description":34,"timeFrame":12},"Proportion of patients who develop adverse events not mentioned in outcomes 4-7","Adverse events are graded according to Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version 5 (CTCAEv5)",{"measure":36,"description":37,"timeFrame":38},"Blood T lymphocyte count at 3 months","Mean T lymphocyte count in blood among evaluable patients","at 3 months",{"measure":40,"description":37,"timeFrame":41},"Blood T lymphocyte count at 1 year","at 1 year",null,{"allocation":44,"interventionModel":45,"interventionModelDescription":42,"primaryPurpose":46,"observationalModel":42,"timePerspective":42,"maskingInfo":47},"NA","SINGLE_GROUP","TREATMENT",{"masking":48,"maskingDescription":42,"whoMasked":42},"NONE","The peripheral stem cell harvest product from the patient's related haploidential donor will be divided into two portions. One portion will undergo T cell receptor (TCR) αβ depletion and the other portion will undergo CD62L depletion. Both depleted products will be infused intravenously to the patient on the same day.",[51],{"label":52,"type":53,"description":54,"interventionNames":55},"Treatment","EXPERIMENTAL","CD62L depleted donor lymphocyte infusion",[56],"Biological: CD62L depleted donor lymphocyte infusion",[58],{"type":59,"name":54,"description":60,"armGroupLabels":61,"otherNames":42},"BIOLOGICAL","Intravenous infusion of CD62L depleted donor lymphocytes",[52],[63],{"name":64,"affiliation":5,"role":65},"Daniel Cheuk","PRINCIPAL_INVESTIGATOR",[67],{"name":64,"role":68,"phone":69,"phoneExt":42,"email":70},"CONTACT","85235136049","cheukkld@gmail.com",[72],{"facility":5,"status":73,"city":74,"state":42,"zip":42,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":81,"contacts":82},"RECRUITING","Hong Kong","HK",{"type":77,"coordinates":78},"Point",[79,80],114.17469,22.27832,{"lat":80,"lon":79},[83],{"name":64,"role":68,"phone":84,"phoneExt":42,"email":70},"852-35136049",{"type":65,"investigatorFullName":86,"investigatorTitle":87,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Cheuk Ka Leung Daniel","Consultant","100518745",false,"NCT06034535","CD62L Depleted Donor Lymphocyte Infusion With T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patient who requires allogeneic hematopoietic stem cell transplant, has no human leukocyte antigen (HLA)-matched sibling donor but has an HLA-haploidentical donor.\n* Adequate organ function to tolerate the conditioning chemotherapy and radiotherapy\n* Karnofsky or Lansky performance status score ≥50\n\nExclusion Criteria:\n\n* Pregnant or lactating woman\n* HIV infection\n* Patients for whom alternative treatment is deemed more appropriate by treating physician\n* Patients who are unlikely to benefit from haploidentical hematopoietic stem cell transplantation, e.g., terminal malignancy with multiorgan failure","ALL","18 Years",{"count":96,"type":97},23,"ESTIMATED","INTERVENTIONAL",[100],"PHASE2","In this clinical trial, the investigators aim to apply CD62L depleted donor lymphocyte infusion (DLI) together with in vitro T cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) to treat patients with malignant or non-malignant disease in need of HSCT. The investigators shall evaluate the graft failure-free, graft-versus-host disease (GVHD)-free survival at one year, frequency of adverse events and post-transplant complications, and immunoreconstitution.",[103],"Hematopoietic Organs; Disorder","2025-09-08",{"date":106,"type":107},"2025-09-15","ACTUAL",{"date":109,"type":107},"2023-09-01",{"date":111,"type":97},"2026-09",{"name":5,"class":6},1]